CIRM approves over $160M to support preclinical and clinical research, advances education opportunities and access to clinical trials
| | | | | | | |

CIRM approves over $160M to support preclinical and clinical research, advances education opportunities and access to clinical trials

On Dec. 11, 2025, the California Institute for Regenerative Medicine (CIRM) governing board approved funding of over $160…

Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
| | | |

Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…